Mark Hahn - Feb 1, 2023 Form 4 Insider Report for Verona Pharma plc (VRNA)

Role
Chief Financial Officer
Signature
/s/ Claire Poll, Attorney-in-fact for Mark Hahn
Stock symbol
VRNA
Transactions as of
Feb 1, 2023
Transactions value $
-$1,056,553
Form type
4
Date filed
2/3/2023, 05:19 PM
Previous filing
Dec 21, 2022
Next filing
May 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRNA Ordinary Shares Sale -$1.06M -413K -2.45% $2.56* 16.4M Feb 1, 2023 Direct F1, F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
F2 The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover taxes in connection with the vesting of certain previously reported Restricted Share Units.
F3 The price reported represents the sale price of the ADSs divided by eight (8).
F4 Consists of (i) 8,223,656 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 1,027,957 ADSs); and (ii) 8,208,656 Ordinary Shares underlying 1,026,082 ADSs.